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Non-small cell lung cancer (NSCLC) is one of most common malignancies and the lead-
ing cause of cancer deaths worldwide. Despite advances in targeted therapies, majority 
of NSCLC patients do not have targetable genomic alterations. Nevertheless, recent 
discovery that NSCLC is an immunogenic tumor type, and several breakthroughs in 
immunotherapies have led to rapid expansion of this new treatment modality in NSCLC 
with recent FDA approvals of programed death receptor-1 inhibitors, such as nivolumab 
and pembrolizumab. Here, we review promising immunotherapeutic approaches in met-
astatic NSCLC, including checkpoint inhibitors, agents with other mechanisms of action, 
and immunotherapy combinations with other drugs. With advent of immunotherapy, 
therapeutic options in metastatic NSCLC are rapidly expanding with the hope to further 
expand life expectancy in metastatic lung cancer.
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iMMUnOTHeRAPY in CAnCeR: inTRODUCTiOn
In 1957, Sir Macfarlane Burnet and Lewis Thomas first recognized the antigenicity of tumors and 
discovered immune surveillance in tumorigenesis (1). However, translation of the use of immune 
system for clinically meaningful benefits has started to realize only recently.
Compared to the circulating tumor antigen-specific T-cells, T-cells in the tumor microenviron-
ment have impaired effector functions (2–4). Mice infected with chronic lymphocytic choriomen-
ingitis virus (LCMV) show upregulation of negative costimulatory receptors on T-cells, including 
cytotoxic T-lymphocyte antigen 4 (CTLA-4), programed death receptor-1 (PD-1), T-cell immuno-
globulin domain and mucin domain-3 (TIM-3), lymphocyte activation gene-3 protein (LAG-3), 
and others (5). The loss of T-cells effector function during chronic infections is similar in cancer 
where T-cells chronically exposed to tumor antigens enter a state of exhaustion (6). Major efforts 
concentrating on reversing T-cell exhaustion by inhibiting negative checkpoints with antibodies 
against PD-1 and its ligand, programed death receptor-1 ligand (PD-L1) are at the forefront of 
immunotherapy research.
Clinical success with immunotherapy was first seen in highly immunogenic malignant melanoma. 
High-dose interleukin-2 (IL-2) showed an objective response rate (ORR) of 16% (7). Interestingly, 
many complete responders experience long-term responses, and IL-2 was used extensively in 
melanoma patients despite high toxicities (8). This changed with approvals of CTLA-4 inhibitor 
ipilimumab in 2011, and PD-1 inhibitors, such as pembrolizumab and nivolumab, in 2014, which 
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have better side effect profiles. The response rates with ipili-
mumab are ~10%, while PD-1 inhibitors have ~40% ORR (8, 9). 
Combination studies of ipilimumab and nivolumab have shown 
ORR of 42–60% (9, 10), unprecedented in melanoma, have led to 
survival benefits and safer treatment options.
Lung cancer has been viewed as non-immunogenic tumor 
where immunotherapies, such as BCG and IL-2, showed no 
efficacy (11, 12). However, with recent success of immune 
checkpoint inhibitors, this has changed, and here we review the 
recent data in non-small cell lung cancer (NSCLC) and emerging 
immunotherapies.
eSTABLiSHeD SinGLe-AGenT 
CHeCKPOinT inHiBiTORS
nivolumab
Nivolumab is a fully human IgG4 antibody against PD-1, which 
can activate host immune system. In phase I studies in pretreated 
NSCLC patients, nivolumab showed ORR of 17–18% (13, 14). 
A phase III trial in patients with advanced squamous NSCLC 
compared nivolumab with docetaxel, demonstrating median 
OS 9.2 vs. 6.2  months (15). In another phase III trial, patients 
with advanced non-squamous NSCLC progressing on platinum-
doublet chemotherapy were randomized to receive nivolumab 
or docetaxel, showing median OS 12.2 months with nivolumab 
and 9.4  months with docetaxel (16). The subgroup of patients 
without numerical progression-free survival (PFS) advantage 
with nivolumab included never smokers, patients with KRAS 
wild type, EGFR-mutant tumors, although this study was not 
powered for subgroup analysis. PD-L1 expression was detected 
by IHC using a human PDL-1 antibody (Epitomics). Cutoffs were 
divided into three groups: 1, 5, and 10%. Quantifiable PDL-1 
expression was seen in 78% patients. OS difference favoring 
nivolumab was found to be significant across all subgroups. No 
meaningful advantage in survival was seen in patients with PDL-
1-negative tumors (16). FDA approved nivolumab for NSCLC 
patients progressing on platinum-doublet chemotherapy in 2015.
The role of nivolumab in patients with Eastern Cooperative 
Oncology Group performance status 2, as maintenance therapy, 
and in combination with other therapies remains to be estab-
lished. A five-arm, phase II basket study has been launched with 
~2000 NSCLC patients including PS2 patients, maintenance 
cohorts, and epidermal growth factor receptor positive (EGFR+)/
anaplasplastic lymphoma kinase positive (ALK+) patients 
treated with erlotinib or crizotinib with and without nivolumab 
(CHECKMATE 370; NCT02574078).
Pembrolizumab
Pembrolizumab is another monoclonal antibody targeting PD-1. 
A randomized phase II/III study compared pembrolizumab with 
docetaxel in advanced NSCLC patients (70% non-squamous, 
22% squamous histology), excluding those with PD-L1-negative 
tumors and stratifying by PDL-1 expression 1–49% (~57% 
patients) and >50% (~43%). The ORR with pembrolizumab was 
~18 vs. 9% with docetaxel, similar to nivolumab studies. The ORR 
in patients with >50% PD-L1 expression was higher: ~30 vs. 8% 
with docetaxel. Median OS was 14.9 months for the pembroli-
zumab 2 mg/kg, 17.3 months for the pembrolizumab 10 mg/kg, 
and 8.2 months for the docetaxel group (17). FDA approved pem-
brolizumab in 2015 for patients with PDL1 + NSCLC patients 
with mandatory immunohistochemistry PD-L1 diagnostic test 
22C3 (Dako).
Atezolizumab
Programed death receptor-1 has two ligands: PD-L1 (B7-H1) and 
PD-L2 (B7-DC) (18, 19). PD-L1 is expressed on hematopoietic, 
endothelial, and epithelial cells (20). Atezolizumab is an IgG1 anti-
body to PD-L1. In a phase II study (POPLAR) of NSCLC patients 
progressing on platinum-based chemotherapy, atezolizumab was 
compared with docetaxel. The median OS for atezolizumab was 
significantly better than with docetaxel (12.6 vs. 9.7  months, 
p =  0.04). The improvement correlated with PD-L1 expression 
on both tumor and tumor-infiltrating immune cells. Although 
the ORR was 15% for both arms, subgroup of patients with high 
PD-L1 expressing tumors had ORR of 38% with atezolizumab 
and 13% with docetaxel (21). In another large single-arm phase 
II study (BIRCH), PD-L1+ patients included treatment-naïve 
NSCLC patients in cohort 1; cohorts 2/3 included patients after 
1–2 lines of chemotherapy. The ORR was 19% in cohort 1, 17% 
in cohorts 2/3. PD-L1 positivity was defined as >5% tumor cells 
positive or >5% tumor area with immune cells staining positive 
(22). FDA has granted priority review for atezolizumab, and final 
decision approval is expected on October 2016.
Durvalumab
Similar to atezolizumab, durvalumab is an IgG1 antibody to 
PD-L1. In a phase I study, durvalumab was administered to 
patients with NSCLC progressing after chemotherapy. Among 
149 patients, ORR was 14% favoring PD-L1+ patients (ORR 
23%) and squamous (ORR 21%) compared to non-squamous 
histology (ORR 10%) (23). In treatment-naive patients with 
advanced NSCLC, ORR was 25% in a recent phase I/II study 
(24). ATLANTIC is an ongoing phase II study with durvalumab 
in NSCLC patients progressing after at least two prior chemo-
therapies (NCT02087423).
Avelumab
Similar to durvalumab, avelumab is a fully human IgG1 antibody 
against PDL1. In a phase Ib study, 184 NSCLC patients progress-
ing on platinum-based chemotherapy, avelumab showed an ORR 
of 12% (14% in PD-L1 + population) (25). JAVELIN lung 100 
is an ongoing phase III trial evaluating avelumab vs. platinum-
based doublet chemotherapy in treatment-naïve NSCLC patients 
(NCT02576574). JAVELIN lung 200 is a phase III trial in patients 
progressing after platinum-based chemotherapy, comparing 
avelumab to docetaxel (NCT02395172).
PD-1, PD-L1 Targeting Agents: Selecting 
the Right Patient Population
Scagliotti et al. first demonstrated difference in survival in NSCLC 
patients treated with platinum-doublet chemotherapy based on 
histology, a biomarker of chemotherapy response. Squamous 
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histology patients did better with cisplatin/gemcitabine, while 
adenocarcinoma patients had improved OS on cisplatin/pem-
etrexed combination (26).
Predicting responses to immunotherapy is more complicated; 
PD-L1 expression is one potential marker. PD-L1 expression 
can change over time. PD-L1 expression at initial tumor biopsy 
does not always correlate with antitumor activity (27). Thommen 
et al. evaluated expression of checkpoints on CD8+ T-cells from 
patients with advanced NSCLC and developed a cumulative 
inhibitory score based on sum expression of several receptors. 
Significant increase in the score was seen in patients with node 
positive, advanced stage, while tumor size did not affect it. An 
inverse correlation between PDL-1 expression and effector func-
tion of CD8+ T-cells treated with PD-1 antibody was observed 
(28). While PD-L1 expression is one of the markers for response 
in NSCLC, prior smoking and high mutational load correlate 
with responsiveness, suggesting that better predictive biomarkers 
or scores are needed (29). Schumacher et  al. developed cancer 
immunogram with seven different immune parameters includ-
ing mutational load to help predict responsiveness of tumors 
to checkpoint inhibitors (30). Efforts should be focused in this 
direction to help identifying the target population and to drive 
down treatment costs.
ipilimumab and Tremelimumab
Ipilimumab and tremelimumab are recombinant monoclonal 
antibodies against cytotoxic CTLA-4 that block CTLA-4 inter-
action with its ligands, such as CD80 and CD86. This blockade 
augments T-cell activation and proliferation, leading to tumor 
infiltration by T-cells and tumor regression (31). Although 
response rates with single-agent CTLA-4 inhibitor in NSCLC 
have been disappointing, there is considerable interest in exploit-
ing this pathway in combination with other checkpoint inhibitors 
(32). In a phase II study, ipilimumab in combination with chemo-
therapy showed modest improvement in PFS in patients with 
advanced NSCLC (33). The benefit was limited to patients who 
received phased ipilimumab, allowing exposure to chemotherapy 
before ipilimumab (33). Encouraging results seen in early stage 
combination trials of CTLA-4 with PD-1 and PD-L1 inhibitors 
are discussed below.
epigenetic Approaches to improve 
immunotherapy Responses
Epigenetic silencing and loss of gene expression is a hallmark 
of cancer (34). DNA-demethylating and histone-deacetylating 
agents show modest benefit in solid tumors (35, 36). Some 
patients may have durable response to subsequent chemotherapy 
or immunotherapy after receiving epigenetic modulators (37). 
Epigenetic therapy could sensitize tumors to subsequent therapy 
by altering tumor genomics, increasing tumor antigenicity (35, 
38, 39). In a phase I/II trial, heavily pretreated NSCLC patients 
received AZA and etinostat. Among 65 patients treated in 
phase II portion, 2 responded (37). Six patients from this trial 
subsequently received PD-1 inhibitors and five of the six patients 
showed PR, including three patients with durable responses for 
14–26 months (40).
Strong preclinical rationales for the combining epigenetic 
drugs with immunotherapy remains, including induction of 
IRF-7 gene, secretion of INF-alpha, synergy between AZA and 
CTLA4, and others (38, 40). Ongoing studies are evaluating pot-
ential combination of demethylating agents and HDAC inhibitors 
with nivolumab, pembrolizumab, and durvalumab, including 
patients failing prior PD-1/PDL-1 therapy (NCT01928576, 
NCT02638090, NCT02437176, NCT02437136, NCT02805660).
eMeRGinG SinGLe-AGenT  
CHeCKPOinT inHiBiTORS
T-Cell immunoglobulin and Mucin  
Domain-3-Containing Molecule 3
With the success of PD-1/PDL-1 and CTLA-4 inhibitors in 
NSCLC, there is an increase interest in exploring other immune 
checkpoint regulators and understanding mechanisms of resist-
ance to checkpoint inhibitors. Ectopic expression of TIM-3 was 
previously reported as an independent negative prognostic factor 
in NSCLC (2). Upregulation of alternative immune checkpoints, 
notably TIM-3, is implicated in PD-1 inhibitors resistance (39). 
Hammerman et  al. showed upregulation of TIM-3 in PD-1 
antibody-bound T-cells and a survival advantage in mice lung 
adenocarcinoma xenografts with addition of TIM-3 antibody 
to PD-1 inhibitor. They found similar upregulation of TIM-3 
in biopsies from patients progressing on PD-1 therapy (41). 
Currently, the first in humans phase I-Ib/II trial is ongoing with 
MBG453 antibody against TIM-3 in combination with PDR001 
PD-1 inhibitor (NCT02608268) in patients with advanced solid 
malignancies, including NSCLC.
Lymphocyte Activation Gene-3
Lymphocyte activation gene-3 is a transmembrane protein, 
closely related to CD4 that binds major histocompatibility com-
plex II (42). LAG-3 is co-negative regulator of effector T cells (43). 
Regulatory T-cells (Tregs) express LAG-3 that is upregulated in 
the presence of effector T-cells, leading to decreased antitumor 
immunity (44). LAG-3 antibodies inhibit Tregs (44). Preclinical 
data in multiple tumors demonstrated prolonged survival with 
dual PD-1/LAG-3 inhibition (45). Tissue samples from patients 
with ovarian epithelial cancers tumor-derived T-lymphocytes 
showed enrichment for coexpression of LAG-3 and PD-1 (46). 
Most of LAG-3 data at this time remain preclinical, and efficacy in 
solid malignancies remains to be seen. Urelumab (BMS-986016) 
and LAG525 are anti-LAG-3 antibodies investigated in early 
phase clinical trials in solid tumors including NSCLC alone and 
in combination with nivolumab or PDR-001 (NCT02658981, 
NCT01968109, NCT02460224).
eMeRGinG SinGLe-AGenT 
iMMUnOMODULATinG DRUGS
Bavituximab
Bavituximab is a chimeric immunoglobulin antibody targeting 
a common phospholipid, phosphatidyl serine (PS), on tumor 
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vascular endothelium (47). In normal cells, PS is expressed on 
internal membrane surface; however, in tumors, it becomes 
exposed on endothelial cells. Bavituximab binds to PS in a 
β2-glycoprotein I-dependent manner leading to antitumor 
effects such as antibody-dependent cell-mediated toxicity. 
Bavituximab prevents interaction between PS on apoptotic 
tumor cells and macrophages and decreases secretion of anti-
inflammatory immunosuppressive molecules, such as TGF-β 
and IL-10 (48, 49).
In a phase II trial, docetaxel +  bavituximab (D +  B) was 
compared to docetaxel + placebo (D + P) in patients with locally 
advanced lung adenocarcinoma. The D + B combination was well 
tolerated, and results were encouraging with an improvement 
of ORR from 11.3% (D +  P arm) to 17.1% (D +  B) (50). The 
confirmatory phase III SUNRISE trial was halted when at 33% 
events it failed to show OS advantage of docetaxel + bavituximab 
combination (NCT01999673). A combination immunotherapy 
trial with durvalumab (PD-L1 inhibitor) and bavituximab in 
recurrent NSCLC is ongoing (NCT02673814).
indoleamine 2,3-Deoxygenase
Indoleamine 2,3-deoxygenase (IDO) is a cytoplasmic tryptophan 
catabolic enzyme that plays a significant role in T-cell suppression 
(51). High levels of IDO were first reported in human placenta 
(52). Inhibition of IDO in mice placenta leads to T-cell-mediated 
rejection of allogeneic conceptii (53). In addition to promoting 
immune tolerance to fetus in placenta, IDO-mediated deple-
tion of tryptophan prevents excessive T-cell activation and lung 
inflammation (54). IDO supports development of immune 
tolerance to tumor antigens, activation of regulatory T-cells, and 
inhibition of cytotoxic T-cells and NK cells and is a relevant target 
in tumor immunology (55).
An ongoing trial is evaluating a combination of IDO inhibitor 
indoximod with docetaxel and Tergenpumatucel-L in NSCLC 
(NCT02460367). Ongoing basket trials in solid malignancies 
including NSCLC are testing other IDO inhibitors alone or 
in combination with checkpoint inhibitors (NCT02048709, 
NCT02073123).
eMeRGinG PD1/PDL1 iMMUnOTHeRAPY 
COMBinATiOnS wiTH CTLA4 
inHiBiTORS, CHeMOTHeRAPY,  
AnD TARGeTeD THeRAPY
Immunotherapy combinations hold promise to further increase 
ORR and OS and outperform chemotherapy in NSCLC in the 
first line settings, based on success of nivolumab/ipilimumab 
combination in metastatic melanoma, now FDA approved based 
on CheckMate067 trial results (56).
Multiple studies are evaluating the role of frontline immu-
notherapy in treatment-naïve NSCLC patients. CheckMate012 
trial included 148 treatment-naïve NSCLC patients with 
PDL-1 expression >1%; 80% patients had non-squamous 
histology. Arm A patients received nivolumab and ipilimumab 
Q3 weeks with ORR 13%, arm B – nivolumab 1  mg/kg Q2 
weeks, ipilimumab 1 mg/kg Q6 weeks, ORR was 25%. Arm C 
had the best ORR of 39% when nivolumab was given 3  mg/
kg Q2 weeks and ipilimumab 1 mg/kg Q12 weeks. Arm D had 
an ORR 31% – nivolumab Q2 weeks, ipilimumab Q6 weeks. 
Median duration of response was not reached (57). A phase II 
single-arm ipilimumab–nivolumab trial in metastatic NSCLC 
is underway (CheckMate 568, NCT02659059). Important 
ongoing phase III studies that might change the treatment 
landscape of NSCLC are KEYNOTE-024 comparing pembroli-
zumab to chemotherapy in PD-L1 + NSCLC, and CheckMate 
026 with nivolumab, both in treatment-naïve advanced NSCLC 
patients.
CheckMate 227, a phase III ipilimumab–nivolumab study 
in treatment-naïve advanced NSCLC in comparison to chemo-
therapy, is ongoing (NCT02477826). Combination of PD-L1 
inhibitor durvalumab and CTLA4 inhibitor tremelimumab was 
recently studied in a phase Ib study of 102 pretreated NSCLC 
patients. Significant dose-limiting toxicities were seen in dur-
valumab 20 mg/kg, tremelimumab 3 mg/kg cohort. Encouraging 
ORR of 23% irrespective of PD-L1 status was observed in 
patients treated with durvalumab 20 mg/kg and tremelimumab 
1  mg/kg (24). MYSTIC and NEPTUNE are ongoing phase III 
studies comparing this combination to platinum-based chemo-
therapy in treatment-naïve NSCLC patients (NCT02453282, 
NCT02542293).
Immunotherapy was pioneered in relatively chemoresistant 
tumors, melanoma, and renal cancer. Historically, platinum-
doublet chemotherapy in NSCLC has ORR ~30% with median OS 
~11–13 months (26, 58, 59). Addition of bevacizumab had mod-
est effect on OS (60). Immunotherapy success in NSCLC opened 
possibilities of combining PD1/PDL1 inhibitors with platinum-
based doublet chemotherapies in a relatively chemosensitive 
tumor. KEYNOTE-021 is one such trial (61). Treatment-naïve 
stage IIIB/IV NSCLC patients were randomized to pembroli-
zumab in combination with carboplatin/paclitaxel (cohort A), 
carboplatin/paclitaxel/bevacizumab (cohort B), and carboplatin/
pemetrexed (cohort C). ORR in cohort C was 71% compared 
with cohort A (52%). Similar ORR was seen in patients express-
ing <1% PD-L1. The carboplatin/pemetrexed/pembrolizumab 
combination is now tested in a larger study (NCT02039674). 
Another phase III trial KENOTE-189 is comparing platinum-
doublet  ±  pembrolizumab in advanced NSCLC patients 
(NCT02578680).
In EGFR or ALK-positive NSCLC, several early phase trials 
are ongoing, combining PD-1 and CTLA-4 checkpoint inhibitors 
with EGFR (erlotinib, afatinib, osimertinib) or ALK (crizotinib) 
tyrosine kinase inhibitors (TKIs) in treatment-naive and previ-
ously treated patients (NCT01998126, NCT02511184). TATTON 
is a multi-arm phase Ib trial of durvalumab with osimertinib. 
Dose escalation arm included EGFR TKI-naïve patients, while 
the expansion cohort included patients progressing on prior 
TKIs. Although the combination showed clinical activity, 38% 
rate of interstitial lung disease was reported with the combina-
tion, disproportionate to what is expected with each agent alone. 
The combination arm has been put on hold (62). A phase I feasi-
bility trial of afatinib and pembrolizumb for patients with EGFR 
mutation-positive NSCLC progressing on erlotinib is recruiting 
(NCT02364609).
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immune-Mediated Toxicity
Immunotherapy is associated with increased frequency of 
immune-related side effects, a spectrum of side effects that are 
broadly termed immune-related adverse events (irAEs) (63). 
irAEs with PD-1/PD-L1 inhibitors are less common (7–13%) 
compared to toxicities with CTLA4 inhibitors (10–18%) (15–17, 
63, 64).
The most frequent side effect with PD-1/PD-L1 inhibitors 
is fatigue, reported among 14–32% patients in phase III studies 
(17–19, 23). Organ-specific common side effects include skin 
toxicities such as rash (9%), diarrhea/colitis (7–8%), hypothy-
roidism (7–8%), hepatitis (1–3%), adrenal insufficiency (1%), 
and thyroiditis (1%) (17–19). Grade 3/4 pneumonitis has been 
reported in NSCLC (3%) with rare treatment-related deaths from 
pneumonitis (64, 65).
Frequency of irAE from combination immunotherapies is 
higher. In phase Ib study of treatment-naïve NSCLC patients 
receiving durvalumab and tremelimumab, serious adverse 
events were reported in 36% patients. The most frequent grade 
3/4 toxicities were diarrhea (11%), colitis (9%), and increased 
lipase (8%) with three treatment-related deaths (24). Toxicity 
analysis from multi-cohort CheckMate 012 showed 29–35% 
grade 3/4 toxicity in nivoluamb plus ipilimumab combination 
arms compared to 19% grade 3/4 toxicity in the nivolumab-only 
arm (57, 66).
COnCLUSiOn
Advances in immunotherapy in metastatic NSCLC now include 
nivolumab and pembrolizumab that are standard in second line 
settings, where both agents significantly improve survival. The 
treatment paradigm changed with introduction of immuno-
therapy and is expected to start impacting first-line treatment 
approaches soon. Ongoing challenges include understanding 
mechanisms of resistance to immunotherapy drugs, development 
of biomarkers, and predictive scores for better patient selection. 
Table 1 summarizes ongoing immunotherapy trials in advanced 
NSCLC, and Figure 1 describes mechanisms of action of select 
agents. New immunotherapy drugs and novel immunotherapy 
combinations in frontline and recurrent settings in NSCLC 
TABLe 1 | Selected immunotherapy studies in metastatic nSCLC.
experimental arm Comparator arm Patient population Trial  
stage
Primary end point (trial identification 
number)
Nivolumab vs. nivolumab + ipilimumab 
vs. nivolumab + platinum-doublet 
chemotherapy (CHECKMATE 227)
Platinum-doublet 
chemotherapy
Treatment naïve stage IV NSCLC III Overall survival progression-free survival 
(NCT02477826)
Nivolumab + ipilimumab  
(CHECKMATE 568)
None-single arm Treatment naïve stage IV NSCLC II Overall response rate (ORR) 
(NCT02659059)
Nivolumab or ipilimumab + erlotinib 
(EGFR mutant) or crizotinib  
(ALK mutant)
None-single arm Stage IV NSCLC failed prior  
platinum-based therapy
I Toxicity of nivolumab or ipilimumab in 
combination with erlotinib (EGFR-mutant 
NSCLC) or crizotinib (ALK mutant NSCLC)
Nivolumab + ALT 803 (novel recombinant 
IL-15 complex)
None Stage IIIb/IV NSCLC failed prior 
platinum-based therapy
Ib/II Phase Ib – dose-limiting toxicity of ALT 
803 nivolumab combination
Phase II – ORR (NCT02523469)
Pembrolizumab + vorinostat None Stage IV NSCLC progressed on  
at least one prior therapy
Ib/II Phase Ib – maximum tolerated dose
Phase II – ORR (NCT02638090)
Pembrolizumab (KEYNOTE-024) Doublet chemotherapy Treatment naïve stage IV NSCLC  
with strongly expressing PD-L1
III PFS (NCT024142738)
Multi-arm pembrolizumab plus 
chemotherapy or immunotherapy 
(KEYNOTE-021)
None Treatment naïve stage IV NSCLC I/II Part I – recommended phase II dose of 
pembrolizumab
Part II – ORR (NCT02039674)
Durvalumab vs. durvalumab plus 
tremelimumab (MYSTIC)
Standard of care platinum-
doublet chemotherapy
Treatment naïve stage IV NSCLC III OS and PFS (NCT02453282)
Durvalumab plus tremelimumab 
(NEPTUNE)
Standard of care platinum-
doublet chemotherapy
Treatment naïve stage IV NSCLC III OS (NCT02542293)
Atezolizumab + carboplatin/
paclitaxel ± bevacizumab
Caboplatin + paclitaxel + 
bevacizumab
Treatment naïve NSCLC –  
non-squamous histology
III PFS (NCT02366143)
Atezolizumab Gemcitabine + ciplatin or 
carboplatin
Treatment naïve NSCLC –  
squamous histology
III PFS (NCT02367794)
MGB453 (anti TIM-3) plus PDR001  
(anti PD-1)
None Multiple advanced solid  
malignancies including NSCLC 
progressed on standard therapy
I–Ib/II Safety and tolerability of MGB453  
in combination with PDR001
ORR (NCT02608268)
LAG525 (anti LAG-3) single agent and in 
combination with PDR001 (anti PD-1)
None Multiple advanced solid  
malignancies including NSCLC 
progressed on standard therapy
I/II Phase I-dose-limiting toxicity
Phase II-ORR
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remains one of the most exciting and rapidly evolving areas in 
oncology, with hope to increase the numbers of long-term survi-
vors with stage IV lung cancer in the near future.
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